Lv3
240 积分 2023-08-22 加入
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
3个月前
已关闭
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
3个月前
已关闭
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
4个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
5个月前
已完结
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
7个月前
已完结
Cancer cell metabolism and antitumour immunity
7个月前
已完结
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
7个月前
已完结
Clonal replacement of tumor-specific T cells following PD-1 blockade
7个月前
已完结
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
8个月前
已完结
皖公网安备34019202002308
